CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: thyroid cancer</title> <meta name="description" content="Search results for: thyroid cancer"> <meta name="keywords" content="thyroid cancer"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="thyroid cancer" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="thyroid cancer"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 2212</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: thyroid cancer</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2212</span> Differentiated Thyroid Cancer Presenting with Solitary Bony Metastases to the Frontal Bone of the Skull</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Christy%20M.%20Moen">Christy M. Moen</a>, <a href="https://publications.waset.org/abstracts/search?q=Richard%20B.%20Townsley"> Richard B. Townsley</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Metastasis to the frontal bone in thyroid cancer is extremely rare. A literature review found only six cases of thyroid cancer that metastasised to the frontal bone, with two of those involving further bone sites. Case Report: The patient was originally referred to the Oral and Maxillofacial Surgery team with an isolated mass on her forehead. Biopsies were performed, which showed this was likely a metastatic deposit from thyroid cancer. CT-PET scan showed this was an isolated lesion. The patient had a total thyroidectomy, and the forehead lesion was managed with radiotherapy. On interval scanning, the patient’s bony lesion had increased in size and had new lung nodules, which likely represented further metastasis. Conclusion: Isolated bony metastases to the frontal bone are rare. An important clinical principle to remember is that a bony metastasis from an unknown primary is more likely than primary bone cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cancer" title="cancer">cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid" title=" thyroid"> thyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=head%20and%20neck" title=" head and neck"> head and neck</a>, <a href="https://publications.waset.org/abstracts/search?q=surgery" title=" surgery"> surgery</a> </p> <a href="https://publications.waset.org/abstracts/138043/differentiated-thyroid-cancer-presenting-with-solitary-bony-metastases-to-the-frontal-bone-of-the-skull" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/138043.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">212</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2211</span> Weight Gain After Total Thyroidectomy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yong%20Seong%20Kim">Yong Seong Kim</a>, <a href="https://publications.waset.org/abstracts/search?q=Seongbin%20Hong"> Seongbin Hong</a>, <a href="https://publications.waset.org/abstracts/search?q=So%20Hun%20Kim"> So Hun Kim</a>, <a href="https://publications.waset.org/abstracts/search?q=Moonsuk%20Nam"> Moonsuk Nam</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Patients who undergo thyroidectomy due to thyroid cancer often complain weight gain, although they are on suppressive thyroid hormone treatment. The aim of this study is to know whether thyroid cancer patients gain the weight after thyroidectomy and weight change is dependent on estrogen state or use of rhTSH. Material and Method: We performed a retrospective chart review of subjects receiving medical care at an academic medical center. Two hundred two patients who underwent total thyroidectomy were included. As a control group, patients with thyroid nodule and euthyroidism were matched for age, gender, menopausal status. The weight changes occurring over first one year and thyroid function were assessed. Results: Mean age was 51±12 years and patients was composed with 38% of premenopausal, 15 % perimenopausal women, 37% of postmenopausal women and 20% of men. Patients with thyroid cancer gained 2.2 kg during the first year. It’ was not significantly different with control. However, weigh change in perimenopausal and post menopausal women gained more weight than control (P <0.05). Age, baseline body weight and weight gain were not correlated. Discussion: Patient who had undergone thyroidectomy gained more weight than their control, especially in peri- and postmenopausal women. Patients in this age should be monitored for their weight carefully. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=weight%20gain" title="weight gain">weight gain</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroidectomy" title=" thyroidectomy"> thyroidectomy</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer" title=" thyroid cancer"> thyroid cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=weight%20chance" title=" weight chance "> weight chance </a> </p> <a href="https://publications.waset.org/abstracts/21104/weight-gain-after-total-thyroidectomy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/21104.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">416</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2210</span> Metastatic Papillary Thyroid Carcinoma in Pleural Effusion- A Very Rare Case</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohammed%20A.%20Abutalib">Mohammed A. Abutalib</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Papillary thyroid carcinoma (PTC) accounts for the most common type of thyroid cancer, a well-differentiated type. PTC is featured by biologically low-grade and less aggressive tumors with a survival rate of 10 years in most of the diagnosed cases. PTC can be presented with the involvement of cervical lymph nodes in about 50% of the patients, yet the distant spread is very uncommon. Herein, we discussed an early 50-year-old male patient with a history of PTC that presented to the emergency department complaining of shortness of breath and a radiological finding of hydrothorax. Cytologic examination, together with immune-histochemical staining and molecular studies of pleural effusion aspiration, concluded the definitive diagnosis of metastatic papillary thyroid carcinoma in the pleural space. PTC seldom causes metastatic niches in the pleural space, and this is a rare clinical presentation; nevertheless, a differential diagnosis of thyroid metastasis needs to be excluded. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer" title="thyroid cancer">thyroid cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=malignant%20pleural%20effusion" title=" malignant pleural effusion"> malignant pleural effusion</a>, <a href="https://publications.waset.org/abstracts/search?q=cytology%20aspiration" title=" cytology aspiration"> cytology aspiration</a>, <a href="https://publications.waset.org/abstracts/search?q=papillary%20thyroid%20carcinoma" title=" papillary thyroid carcinoma"> papillary thyroid carcinoma</a> </p> <a href="https://publications.waset.org/abstracts/164368/metastatic-papillary-thyroid-carcinoma-in-pleural-effusion-a-very-rare-case" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/164368.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">105</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2209</span> A Four-Year Study of Thyroid Carcinoma in Hail Region: Increased Incidence</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Laila%20Seada">Laila Seada</a>, <a href="https://publications.waset.org/abstracts/search?q=Hanan%20Oreiby"> Hanan Oreiby</a>, <a href="https://publications.waset.org/abstracts/search?q=Fawaz%20Al%20Rashid"> Fawaz Al Rashid</a>, <a href="https://publications.waset.org/abstracts/search?q=Ashraf%20Negm"> Ashraf Negm</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background and Objective: In most areas of the world, the incidence of thyroid cancer has been increasing over the last decade, mostly due to a combination of early detection of the neoplasm resulting from sensitive procedures and increased population exposure to radiation and unrecognized carcinogens. Methods: Cases of thyroid cancer have been retrieved from the cancer registry at King Khalid Hospital during the period from August 2012 to April 2016. Age, gender and histopathologic types have been recorded. Results: Thyroid carcinoma ranked as the second most common malignancy in females (25%) after breast cancer (31%). It constituted 20.8% of all newly diagnosed cancer cases. As for males, it ranked the 4<sup>th</sup> type of malignancy after gastrointestinal cancer, lymphomas and soft tissue sarcomas. Mean age for females and males was 38.7 +/- 13.2 and 60.25 +/- 11.5 years, respectively, and the difference between the two groups was statistically significant (<em>p</em> value = 0.0001). Fifty-five (82%) were papillary carcinomas including 10 follicular variant of papillary (FVPC), and eight papillary micro carcinomas (PMC) and two tall cell/oncocytic variants. Follicular carcinomas constituted two (3.1%), while two (3.1%) were anaplastic, and two (3.1%) were medullary. Conclusion: Thyroid cancer incidence in Hail is ranking as the 2<sup>nd</sup> most common female malignancy similar to other regions in the Kingdom. However, this high incidence contrasts with much lower rates worldwide. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid" title="thyroid">thyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=hail" title=" hail"> hail</a>, <a href="https://publications.waset.org/abstracts/search?q=papillary" title=" papillary"> papillary</a>, <a href="https://publications.waset.org/abstracts/search?q=microcarcinoma" title=" microcarcinoma"> microcarcinoma</a> </p> <a href="https://publications.waset.org/abstracts/53170/a-four-year-study-of-thyroid-carcinoma-in-hail-region-increased-incidence" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/53170.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">308</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2208</span> Recurrence of Papillary Thyroid Cancer with an Interval of 40 Years. Report of an Autopsy Case</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Satoshi%20Furukawa">Satoshi Furukawa</a>, <a href="https://publications.waset.org/abstracts/search?q=Satomu%20Morita"> Satomu Morita</a>, <a href="https://publications.waset.org/abstracts/search?q=Katsuji%20Nishi"> Katsuji Nishi</a>, <a href="https://publications.waset.org/abstracts/search?q=Masahito%20Hitosugi"> Masahito Hitosugi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A 75-year-old woman took thyroidectomy forty years previously. Enlarged masses were seen at autopsy just above and below the left clavicle. We proved the diagnosis of papillary thyroid cancer (PTC) and lung metastasis by histological examinations. The prognosis of PTC is excellent; the 10-year survival rate ranges between 85 and 99%. Lung metastases may be found in 10% of the patients with PTC. We report an unusual case of recurrence of PTC with metastasis to the lung. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=papillary%20thyroid%20cancer" title="papillary thyroid cancer">papillary thyroid cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=lung%20metastasis" title=" lung metastasis"> lung metastasis</a>, <a href="https://publications.waset.org/abstracts/search?q=autopsy" title=" autopsy"> autopsy</a>, <a href="https://publications.waset.org/abstracts/search?q=histopathological%20findings" title=" histopathological findings "> histopathological findings </a> </p> <a href="https://publications.waset.org/abstracts/13909/recurrence-of-papillary-thyroid-cancer-with-an-interval-of-40-years-report-of-an-autopsy-case" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/13909.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">340</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2207</span> The Differences of Vascular Endothelial Growth Factor Levels in Serum to Determine Follicular Adenoma and Follicular Carcinoma of Thyroid</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tery%20Nehemia%20Nugraha%20Joseph">Tery Nehemia Nugraha Joseph</a>, <a href="https://publications.waset.org/abstracts/search?q=J.%20D.%20P.%20Wisnubroto"> J. D. P. Wisnubroto</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Thyroid cancer is a healthcare problem with high morbidity and mortality. Follicular adenoma and follicular carcinoma are thyroid tumors from the thyroid follicular cells differentiation with a microfollicular pattern that consists of follicular cuboidal cells. vascular endothelial growth factor (VEGF) is a potent and powerful mitogen for endothelial cells and increases vascular permeability. Therefore, due to an increase in thyroid-stimulating hormone (TSH), VEGF production is activated in the thyroid that leads to the end of mitogenic TSH stimulation and initiation of angiogenesis. The differences in VEGF levels in the follicular carcinoma of thyroid tissue with follicular adenoma thyroid can be used as a basis in differentiating the two types of neoplasms. This study aims to analyze VEGF in the serum so that it can be used to differentiate the types of thyroid carcinoma before surgery. This study uses a cross-sectional research design. Samples were carried out by taking serum samples, and the VEGF levels were calculated. Data were analyzed using the Mann-Whitney test. The results found a significant difference between VEGF levels in the follicular carcinoma thyroid group and VEGF levels in the follicular adenoma thyroid group with a value of p = 0.007 (p < 0.05). The results obtained are 560,427 ± 160,506 ng/mL in the type of follicular carcinoma thyroid and 320.943 ± 134.573 ng/mL in the type of follicular adenoma thyroid. VEGF levels between follicular adenoma and follicular carcinoma are different. VEGF levels are higher in follicular carcinoma thyroid than follicular adenoma thyroid. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=follicular%20adenoma%20thyroid" title="follicular adenoma thyroid">follicular adenoma thyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=follicular%20carcinoma%20thyroid" title=" follicular carcinoma thyroid"> follicular carcinoma thyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid" title=" thyroid"> thyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=VEGF" title=" VEGF"> VEGF</a> </p> <a href="https://publications.waset.org/abstracts/136980/the-differences-of-vascular-endothelial-growth-factor-levels-in-serum-to-determine-follicular-adenoma-and-follicular-carcinoma-of-thyroid" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/136980.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">142</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2206</span> Development of a Bi-National Thyroid Cancer Clinical Quality Registry</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Liane%20J.%20Ioannou">Liane J. Ioannou</a>, <a href="https://publications.waset.org/abstracts/search?q=Jonathan%20Serpell"> Jonathan Serpell</a>, <a href="https://publications.waset.org/abstracts/search?q=Joanne%20Dean"> Joanne Dean</a>, <a href="https://publications.waset.org/abstracts/search?q=Cino%20Bendinelli"> Cino Bendinelli</a>, <a href="https://publications.waset.org/abstracts/search?q=Jenny%20Gough"> Jenny Gough</a>, <a href="https://publications.waset.org/abstracts/search?q=Dean%20Lisewski"> Dean Lisewski</a>, <a href="https://publications.waset.org/abstracts/search?q=Julie%20Miller"> Julie Miller</a>, <a href="https://publications.waset.org/abstracts/search?q=Win%20Meyer-Rochow"> Win Meyer-Rochow</a>, <a href="https://publications.waset.org/abstracts/search?q=Stan%20Sidhu"> Stan Sidhu</a>, <a href="https://publications.waset.org/abstracts/search?q=Duncan%20Topliss"> Duncan Topliss</a>, <a href="https://publications.waset.org/abstracts/search?q=David%20Walters"> David Walters</a>, <a href="https://publications.waset.org/abstracts/search?q=John%20Zalcberg"> John Zalcberg</a>, <a href="https://publications.waset.org/abstracts/search?q=Susannah%20Ahern"> Susannah Ahern</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The occurrence of thyroid cancer is increasing throughout the developed world, including Australia and New Zealand, and since the 1990s has become the fastest increasing malignancy. Following the success of a number of institutional databases that monitor outcomes after thyroid surgery, the Australian and New Zealand Endocrine Surgeons (ANZES) agreed to auspice the development of a bi-national thyroid cancer registry. Objectives: To establish a bi-national population-based clinical quality registry with the aim of monitoring and improving the quality of care provided to patients diagnosed with thyroid cancer in Australia and New Zealand. Patients and Methods: The Australian and New Zealand Thyroid Cancer Registry (ANZTCR) captures clinical data for all patients, over the age of 18 years, diagnosed with thyroid cancer, confirmed by histopathology report, that have been diagnosed, assessed or treated at a contributing hospital. Data is collected by endocrine surgeons using a web-based interface, REDCap, primarily via direct data entry. Results: A multi-disciplinary Steering Committee was formed, and with operational support from Monash University the ANZTCR was established in early 2017. The pilot phase of the registry is currently operating in Victoria, New South Wales, Queensland, Western Australia and South Australia, with over 30 sites expected to come on board across Australia and New Zealand in 2018. A modified-Delphi process was undertaken to determine the key quality indicators to be reported by the registry, and a minimum dataset was developed comprising information regarding thyroid cancer diagnosis, pathology, surgery, and 30-day follow up. Conclusion: There are very few established thyroid cancer registries internationally, yet clinical quality registries have shown valuable outcomes and patient benefits in other cancers. The establishment of the ANZTCR provides the opportunity for Australia and New Zealand to further understand the current practice in the treatment of thyroid cancer and reasons for variation in outcomes. The engagement of endocrine surgeons in supporting this initiative is crucial. While the pilot registry has a focus on early clinical outcomes, it is anticipated that future collection of longer-term outcome data particularly for patients with the poor prognostic disease will add significant further value to the registry. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer" title="thyroid cancer">thyroid cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=clinical%20registry" title=" clinical registry"> clinical registry</a>, <a href="https://publications.waset.org/abstracts/search?q=population%20health" title=" population health"> population health</a>, <a href="https://publications.waset.org/abstracts/search?q=quality%20improvement" title=" quality improvement"> quality improvement</a> </p> <a href="https://publications.waset.org/abstracts/95307/development-of-a-bi-national-thyroid-cancer-clinical-quality-registry" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/95307.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">192</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2205</span> Role of F18-FDG PET in Management of Differentiated Thyroid Cancers (TENIS) Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Seemab%20Safdar">Seemab Safdar</a>, <a href="https://publications.waset.org/abstracts/search?q=Shazia%20Fatima"> Shazia Fatima</a>, <a href="https://publications.waset.org/abstracts/search?q=Ahmad%20Qureshy"> Ahmad Qureshy</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Adnan%20Saeed"> M. Adnan Saeed</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Faheem"> M. Faheem</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Thyroid cancer has 586,000 cases per year worldwide, and this translates to 3% of all tumor diagnoses. 90% of the cases fall under differentiated thyroid carcinoma (DTC), which includes follicular thyroid cancer (FTC) and papillary thyroid cancer (PTC). During their illness, 10% of patients develop distant metastases, and two-thirds of them develop resistance to radioactive iodine (RAI) treatment. It has been shown that in some circumstances, like DTC with high TG levels and negative 131I whole-body scintigraphy (TENIS), [18F] FDG-PET-CT is an effective imaging technique. This study determines the role of [18F] FDG-PET-CT in the treatment of TENIS patients. Methods: 16 patients (n = 12 female; 4 males, age 45 ± 15 years) with histologically proven thyroid cancer (Differentiated and poorly differentiated) and high TG with negative iodine scans were included in this prospective study from January 2024 to June 2024. They underwent scanning in state-of-the-art (GE Discovery MI) [18F] FDG-PET-CT for re-staging or diagnostics of recurrent disease using a standardized protocol. All DTC subtypes and PDTC were included. The referring physicians completed standardized questionnaires both before and after PET-CT to prospectively determine the examination's effect on clinical decision-making. Patient outcomes were measured by analysis of medical records. Moreover, after PET-CT, a change in the pre-PET-CT planned therapies was documented in 32% of cases and additional invasive diagnostic procedures could be waived in 37.5 % of cases. TG levels under TSH stimulation were significantly higher in patients showing PET-CT metastases compared to patients without such findings (68.75%). Results: Without PET-CT, physicians referring to the doctors had not established a complete treatment plan for 45% of patients with thyroid carcinoma. 12/16 patients showed FDG avidity in cervical lymph nodes that were not Iodine avid previously, 2 patients had FDG avid disease in the lungs. In the process, PET-CT helped plan patient management and created a clear plan for treatment in 68.75% of patients. Conclusions: This study confirms that [18F] FDG-PET-CT used in a routine clinical setting has a very important impact on the management of patients with thyroid cancer when TG levels are persistently high in the presence of negative Iodine Scans by initiating treatments and replacing additional imaging and invasive tests. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=PET-CT" title="PET-CT">PET-CT</a>, <a href="https://publications.waset.org/abstracts/search?q=TENIS" title=" TENIS"> TENIS</a>, <a href="https://publications.waset.org/abstracts/search?q=role" title=" role"> role</a>, <a href="https://publications.waset.org/abstracts/search?q=FDG" title=" FDG"> FDG</a> </p> <a href="https://publications.waset.org/abstracts/192538/role-of-f18-fdg-pet-in-management-of-differentiated-thyroid-cancers-tenis-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/192538.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">14</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2204</span> Modification of the Risk for Incident Cancer with Changes in the Metabolic Syndrome Status: A Prospective Cohort Study in Taiwan</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Yung-Feng%20Yen">Yung-Feng Yen</a>, <a href="https://publications.waset.org/abstracts/search?q=Yun-Ju%20Lai"> Yun-Ju Lai</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Metabolic syndrome (MetS) is reversible; however, the effect of changes in MetS status on the risk of incident cancer has not been extensively studied. We aimed to investigate the effects of changes in MetS status on incident cancer risk. Methods: This prospective, longitudinal study used data from Taiwan’s MJ cohort of 157,915 adults recruited from 2002–2016 who had repeated MetS measurements 5.2 (±3.5) years apart and were followed up for the new onset of cancer over 8.2 (±4.5) years. A new diagnosis of incident cancer in study individuals was confirmed by their pathohistological reports. The participants’ MetS status included MetS-free (n=119,331), MetS-developed (n=14,272), MetS-recovered (n=7,914), and MetS-persistent (n=16,398). We used the Fine-Gray sub-distribution method, with death as the competing risk, to determine the association between MetS changes and the risk of incident cancer. Results: During the follow-up period, 7,486 individuals had new development of cancer. Compared with the MetS-free group, MetS-persistent individuals had a significantly higher risk of incident cancer (adjusted hazard ratio [aHR], 1.10; 95% confidence interval [CI], 1.03-1.18). Considering the effect of dynamic changes in MetS status on the risk of specific cancer types, MetS persistence was significantly associated with a higher risk of incident colon and rectum, kidney, pancreas, uterus, and thyroid cancer. The risk of kidney, uterus, and thyroid cancer in MetS-recovered individuals was higher than in those who remained MetS but lower than MetS-persistent individuals. Conclusions: Persistent MetS is associated with a higher risk of incident cancer, and recovery from MetS may reduce the risk. The findings of our study suggest that it is imperative for individuals with pre-existing MetS to seek treatment for this condition to reduce the cancer risk. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=metabolic%20syndrome%20change" title="metabolic syndrome change">metabolic syndrome change</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=risk%20factor" title=" risk factor"> risk factor</a>, <a href="https://publications.waset.org/abstracts/search?q=cohort%20study" title=" cohort study"> cohort study</a> </p> <a href="https://publications.waset.org/abstracts/161544/modification-of-the-risk-for-incident-cancer-with-changes-in-the-metabolic-syndrome-status-a-prospective-cohort-study-in-taiwan" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/161544.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">78</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2203</span> Thyroid-Stimulating Hormone as a Stress Biomarker in Thyroidectomy Patients: A Cohort Study</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Jeonghun%20Lee">Jeonghun Lee</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In this study, we investigated the relationship between stress and thyroid dysfunction in such patients who underwent thyroidectomy. This study included 101 patients who underwent thyroidectomy from January 2015 to June 2020 and experienced hypothyroidism. The included patients had good drug compliance with the same dosage of levothyroxine (LT4). The male-to-female ratio was 1:4.6, and the mean age was 45.4 years at surgery and 50.2 years at stressful events. Eighteen patients underwent lobectomies and, of these, 12 did not take LT4. The mean follow-up period was 49(8-93) months. Statistical analyses were performed using the paired t-test, Wilcoxon signed-rank test, and McNemer test using PROC MIXED with SAS 9.4. Forty-five patients (44.6%) had hypothyroidism with thyroid-stimulating hormone (TSH) >10 μIU/mL. There was distress in 81 patients and eustress in 10 patients. TSH levels increased during a mean 5.8 months (min 1, max 12) in 24 patients who specified the date of their life events. Even though each patient took the same dose of LT4, when the patients were under stress, both the free T4 and T3 decreased and TSH increased, regardless of whether the patient experienced distress or eustress (P <0.001). While adjusting for the effect of the free T4 and T3, TSH increased significantly in the patients after stress (P <0.001). For patients with thyroid cancer who are simultaneously experiencing life events, TSH may be used as a stress biomarker to enable the implementation of appropriate treatment and counseling strategies. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=endocrine" title="endocrine">endocrine</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid" title=" thyroid"> thyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20function" title=" thyroid function"> thyroid function</a>, <a href="https://publications.waset.org/abstracts/search?q=biomarker" title=" biomarker"> biomarker</a>, <a href="https://publications.waset.org/abstracts/search?q=stress" title=" stress"> stress</a> </p> <a href="https://publications.waset.org/abstracts/151409/thyroid-stimulating-hormone-as-a-stress-biomarker-in-thyroidectomy-patients-a-cohort-study" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/151409.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">87</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2202</span> Thyroid Malignancy Concurrent with Hyperthyroidism: Variations with Thyroid Status and Age</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=N.%20J.%20Nawarathna">N. J. Nawarathna</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20R.%20Kmarasinghe"> N. R. Kmarasinghe</a>, <a href="https://publications.waset.org/abstracts/search?q=D.%20Chandrasekara"> D. Chandrasekara</a>, <a href="https://publications.waset.org/abstracts/search?q=B.%20M.%20R.%20S.%20Balasooriya"> B. M. R. S. Balasooriya</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20A.%20A.%20Shaminda"> R. A. A. Shaminda</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20J.%20K.%20Senevirathne"> R. J. K. Senevirathne</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Thyroid malignancy associated with hyperthyroidism is considered rare. Retrospective studies have shown the incidence of thyroid malignancy in hyperthyroid patients to be low (0.7-8.5%). To assess the clinical relevance of this association, thyroid status in a cohort of patients with thyroid malignancy were analyzed. Method: Thyroid malignancies diagnosed histologically in 56 patients, over a 18 month period beginning from April 2013, in a single surgical unit at Teaching Hospital Kandy were included. Preoperative patient details and progression of thyroid status were asessed with Thyroid Stimulating Hormone, free Thyroxin and free Triiodothyronine levels. Results: Amongst 56 patients Papillary carcinoma was diagnosed in 44(78.6%), follicular carcinomas in 7(12.5%) and 5(8.9%) with medullary and anaplastic carcinomas. 12(21.4%) were males and 44(78.6%) were females. 20(35.7%) were less than 40years, 29(51.8%) were between 40 to 59years and 7(12.5%) were above 59years. Cross tabulation of Type of carcinoma with Gender revealed likelihood ratio of 6.908, Significance p = 0.032. Biochemically 12(21.4%) were hyperthyroid. Out of them 5(41.7%) had primary hyperthyroidism and 7(58.3%) had secondary hyperthyroidism. Mean age of euthyroid patients was 43.77years (SD 10.574) and hyperthyroid patients was 53.25years(SD 16.057). Independent Samples Test t is -2.446, two tailed significance p =0.018. When cross tabulate thyroid status with Age group Likelihood Ratio was 9.640, Significance p = 0.008. Conclusion: Papillary carcinoma is seen more among females. Among the patients with thyroid carcinomas, those with biochemically proven hyperthyroidism were more among the older age group than those who were euthyroid. Hence careful evaluation of elderly hyperthyroid patients to select the most suitable therapeutic approach is justified. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=age" title="age">age</a>, <a href="https://publications.waset.org/abstracts/search?q=hyperthyroidism" title=" hyperthyroidism"> hyperthyroidism</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20malignancy" title=" thyroid malignancy"> thyroid malignancy</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20status" title=" thyroid status"> thyroid status</a> </p> <a href="https://publications.waset.org/abstracts/21237/thyroid-malignancy-concurrent-with-hyperthyroidism-variations-with-thyroid-status-and-age" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/21237.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">403</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2201</span> Calculation of Secondary Neutron Dose Equivalent in Proton Therapy of Thyroid Gland Using FLUKA Code</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20R.%20Akbari">M. R. Akbari</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Sadeghi"> M. Sadeghi</a>, <a href="https://publications.waset.org/abstracts/search?q=R.%20Faghihi"> R. Faghihi</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20A.%20Mosleh-Shirazi"> M. A. Mosleh-Shirazi</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20R.%20Khorrami-Moghadam"> A. R. Khorrami-Moghadam</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Proton radiotherapy (PRT) is becoming an established treatment modality for cancer. The localized tumors, the same as undifferentiated thyroid tumors are insufficiently handled by conventional radiotherapy, while protons would propose the prospect of increasing the tumor dose without exceeding the tolerance of the surrounding healthy tissues. In spite of relatively high advantages in giving localized radiation dose to the tumor region, in proton therapy, secondary neutron production can have significant contribution on integral dose and lessen advantages of this modality contrast to conventional radiotherapy techniques. Furthermore, neutrons have high quality factor, therefore, even a small physical dose can cause considerable biological effects. Measuring of this neutron dose is a very critical step in prediction of secondary cancer incidence. It has been found that FLUKA Monte Carlo code simulations have been used to evaluate dose due to secondaries in proton therapy. In this study, first, by validating simulated proton beam range in water phantom with CSDA range from NIST for the studied proton energy range (34-54 MeV), a proton therapy in thyroid gland cancer was simulated using FLUKA code. Secondary neutron dose equivalent of some organs and tissues after the target volume caused by 34 and 54 MeV proton interactions were calculated in order to evaluate secondary cancer incidence. A multilayer cylindrical neck phantom considering all the layers of neck tissues and a proton beam impinging normally on the phantom were also simulated. Trachea (accompanied by Larynx) had the greatest dose equivalent (1.24×10-1 and 1.45 pSv per primary 34 and 54 MeV protons, respectively) among the simulated tissues after the target volume in the neck region. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=FLUKA%20code" title="FLUKA code">FLUKA code</a>, <a href="https://publications.waset.org/abstracts/search?q=neutron%20dose%20equivalent" title=" neutron dose equivalent"> neutron dose equivalent</a>, <a href="https://publications.waset.org/abstracts/search?q=proton%20therapy" title=" proton therapy"> proton therapy</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20gland" title=" thyroid gland"> thyroid gland</a> </p> <a href="https://publications.waset.org/abstracts/11492/calculation-of-secondary-neutron-dose-equivalent-in-proton-therapy-of-thyroid-gland-using-fluka-code" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/11492.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">425</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2200</span> Thyroid Hormones and Thyrotropin Status in Nepalese Postmenopausal Women</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=S.%20A.%20Khan">S. A. Khan</a>, <a href="https://publications.waset.org/abstracts/search?q=B.%20Mishra"> B. Mishra</a>, <a href="https://publications.waset.org/abstracts/search?q=O.%20Sherchan"> O. Sherchan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background and Aims: Thyroid disorder is the most common endocrine disorder after diabetes mellitus. Females are more vulnerable to this disease, and old age is an important risk factor. This study was undertaken to investigate the burden of thyroid disorder in Nepalese postmenopausal women. Methods: In the present cross-sectional study, we included 271 post-menopausal women. Three ml of blood was collected following standard protocol after taking the written consent. Serum was separated and analyzed for free T3, free T4, and Thyroid Stimulating Hormone (TSH) by Chemiluminescence Immunoassay (CLIA) method in Snibe Maglumi 1000 analyzer. Data obtained was analyzed in SPSS Version 21. P < 0.05 was set for statistical significant at 95% Confidence Interval (CI). Results: Majority of the participants belong to Janjati (46.5%) ethnicity, followed by Brahmin/Chhetri (41.7%), residing either in urban or suburban locality. Most of them were non-vegetarian, non-smoker, and non-alcoholic. Subjects were divided into hyperthyroid (TSH < 0.3 uIU/ml), hypothyroid (TSH > 4.5 uIU/ml), and euthyroid (TSH=0.3-4.5 uIU/ml) based on TSH value. We reported 10.3% hyperthyroid and 29.2% hypothyroid cases. TSH was significantly correlated with T3 (r=-0.244; p < 0.001) T4 (r=-0.398; p < 0.001); age (r=-0.138; p=0.023) and BMI (r=0.123; p=0.043). Multiple linear regression model for TSH reveals only T3 and T4 were significantly associated with TSH (p < 0.001; p=0.001). Conclusion: To conclude, nearly 39.5% of the postmenopausal women had thyroid disorder. Postmenopausal women are vulnerable to thyroid disorder; therefore, requires regular thyroid monitoring. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid%20stimulating%20hormone" title="thyroid stimulating hormone">thyroid stimulating hormone</a>, <a href="https://publications.waset.org/abstracts/search?q=TSH" title=" TSH"> TSH</a>, <a href="https://publications.waset.org/abstracts/search?q=T3" title=" T3"> T3</a>, <a href="https://publications.waset.org/abstracts/search?q=T4" title=" T4"> T4</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20disorder" title=" thyroid disorder"> thyroid disorder</a> </p> <a href="https://publications.waset.org/abstracts/124840/thyroid-hormones-and-thyrotropin-status-in-nepalese-postmenopausal-women" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/124840.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">131</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2199</span> Thyroid Dysfunction in Patients with Chronic Hemodialysis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Benghezel%20Hichem">Benghezel Hichem</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Thyroid dysfunction in hemodialysis subjects is represented mainly by hypothyroidism. The objective of our work is to determine the thyroid profile of our hemodialysis patients and to highlight the prevalence of different thyroid disorders. Methods: This is a retrospective study performed on a mono centric 2 months (February and March 2013) on 42 hemodialysis patients (11 male and 31 female). We made the dosage of thyroid hormones Thyrotropin (TSH) ((free thyroxin ) FT4 and free Triodothyronin ) FT3) by chemiluminescence immunoassay method on cobas 6000 Roche Diagnostics. The results: The prevalence of biological hypothyroidism was 18% (7% with a high TSH isolated and a mean +/- SD 9.44 +/- 6.29, 5% with high TSH, and with low FT4 a mean +/- SD is 8.18 +/- 0.53 for TSH and 9.69 +/- 0.22 for FT4, One patient with a high TSH, and low FT4, FT3. 4% of patients with a low T3 syndrome with a mean +/- SD of 3.93 +/- 0,3 for FT3), we notice that 5% of patients with hyperthyroidism TSH collapsed and mean +/- SD of TSH is 0.017 +/- 0,001. Conclusion: The biological Hypothyroidism is a common endocrine disorder in chronic hemodialysis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hypothyroidism" title="hypothyroidism">hypothyroidism</a>, <a href="https://publications.waset.org/abstracts/search?q=hemodialysis" title=" hemodialysis"> hemodialysis</a>, <a href="https://publications.waset.org/abstracts/search?q=thyr%C3%A9ostimulin" title=" thyréostimulin"> thyréostimulin</a>, <a href="https://publications.waset.org/abstracts/search?q=free%20thyroxin" title=" free thyroxin"> free thyroxin</a>, <a href="https://publications.waset.org/abstracts/search?q=triodothyronin" title=" triodothyronin"> triodothyronin</a> </p> <a href="https://publications.waset.org/abstracts/42006/thyroid-dysfunction-in-patients-with-chronic-hemodialysis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/42006.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">422</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2198</span> Prevalence of Autoimmune Thyroid Disease in Recurrent Aphthous Stomatitis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Arghavan%20Tonkaboni">Arghavan Tonkaboni</a>, <a href="https://publications.waset.org/abstracts/search?q=Shamsolmolouk%20Najafi"> Shamsolmolouk Najafi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohmmad%20Taghi%20Kiani"> Mohmmad Taghi Kiani</a>, <a href="https://publications.waset.org/abstracts/search?q=Mehrzad%20Gholampour"> Mehrzad Gholampour</a>, <a href="https://publications.waset.org/abstracts/search?q=Touraj%20Goli"> Touraj Goli</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Recurrent aphthous stomatitis (RAS) is a multifactorial recurrent oral lesion; which is an autoimmune disease. TH1 cytokines are the most important etiological factors. Autoimmune thyroid disease (ATD) is one of the most common autoimmune diseases and generally coexists with other autoimmune diseases. This study assessed the prevalence of thyroid disease in patients with recurrent aphthous stomatitis. Materials and Methods: This case control study assessed 100 known RAS patients who were diagnosed clinically by oral medicine specialists; venous blood samples were analyzed for thyroid stimulating hormone (TSH), free triiodothyronine (fT3), total thyroxine (fT4), thyroglobulin, anti-thyroid peroxidase antibody (anti-TPO) and anti-thyroglobulin antibody (anti-TG) levels. Results: Fifty patients with RAS aged between 18-42 years (28.5±5.8) and 50 healthy volunteers aged 19-45 years (27.3±5.4) participated. In RAS patients, fT3 and TSH levels were significantly higher (P=0.031, P=0.706); however, fT4 level was lower in the RAS group (P=0.447). Anti TG and anti-TPO levels were significantly higher in the RAS group (P=0.008, P=0.067). Conclusion: Our study showed that ATD prevalence was significantly higher in RAS patients. Based on this study, we recommend assessment of thyroid hormones and antibodies in RAS patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=recurrent%20aphthous%20stomatitis" title="recurrent aphthous stomatitis">recurrent aphthous stomatitis</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20antibodies" title=" thyroid antibodies"> thyroid antibodies</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20hormone" title=" thyroid hormone"> thyroid hormone</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20autoimmune%20disease" title=" thyroid autoimmune disease"> thyroid autoimmune disease</a> </p> <a href="https://publications.waset.org/abstracts/41767/prevalence-of-autoimmune-thyroid-disease-in-recurrent-aphthous-stomatitis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/41767.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">342</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2197</span> Evaluation of Prevalence of the Types of Thyroid Disorders Using Ultrasound and Pathology of One-Humped Camel in Iran: Camelus dromedarius</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=M.%20Yadegari">M. Yadegari</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The thyroid gland is the largest classic endocrine organ that effects many organs of the body and plays a significant role in the process of Metabolism in animals. The aim of this study was to investigate the prevalence of thyroid disorders diagnosed by ultrasound and microscopic Lesions of the thyroid during the slaughter of apparently healthy One Humped Camels (Camelus dromedarius) in Iran. Randomly, 520 male camels (With an age range of 4 to 8 years), were studied in 2012 to 2013. The Camels’ thyroid glands were evaluated by sonographic examination. In both longitudinal and transverse view and then tissue sections were provide and stained with H & E and finally examined by light microscopy. The results obtained indicated the following: hyperplastic goiter (21%), degenerative changes (12%), follicular cysts (8%), follicular atrophy (4%), nodular hyperplasia (3%), adenoma (1%), carcinoma (1%) and simple goiter colloid (1%). Ultrasound evaluation of thyroid gland in adenoma and carcinoma showed enlargement and irregular of the gland, decreased echogenicity, and the heterogeneous thyroid parenchyma. Also, in follicular cysts were observed in the enlarged gland with no echo structures of different sizes and decreased echogenicity as a local or general. In nodular hyperplasia, increase echogenicity and heterogeneous parenchymal were seen. These findings suggest the use of Ultrasound as a screening test in the diagnosis of complications of thyroid disorders. Pathology also to be used for the diagnosis of thyroid problems and other side effects. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid%20gland" title="thyroid gland">thyroid gland</a>, <a href="https://publications.waset.org/abstracts/search?q=one%20humped%20camel" title=" one humped camel"> one humped camel</a>, <a href="https://publications.waset.org/abstracts/search?q=sonography" title=" sonography"> sonography</a>, <a href="https://publications.waset.org/abstracts/search?q=pathology" title=" pathology"> pathology</a> </p> <a href="https://publications.waset.org/abstracts/21055/evaluation-of-prevalence-of-the-types-of-thyroid-disorders-using-ultrasound-and-pathology-of-one-humped-camel-in-iran-camelus-dromedarius" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/21055.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">508</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2196</span> The Proportion of and Factors Associated With Thyroid Dysfunction among Individuals Referred To A Tertiary Care Facility in Kabul, Afghanistan</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Naeem%20Lakanwall">Mohammad Naeem Lakanwall</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background:The thyroid gland, located just below the vocal cord on each side of and anterior to the trachea, is one of the main endocrine glands. Its normal weight is 15 to 20 grams in adults. The thyroid secretes two most important hormones, thyroxine and triiodothyronine, usually called T4 and T3, respectively. These hormones greatly increase the metabolic rate of the body. In addition to T3 and T4, the thyroid gland secrets calcitonin as well which is a significant hormone for calcium metabolism. Objective: The aim of this study is to estimate the proportion of and to identify factors associated with thyroid dysfunction among individuals coming to a tertiary care facility in Kabul, Afghanistan. Material and Methods: An analytical cross-sectional study design was conducted from July to Sep 2018. Blood samples were obtained, serum TSH levels were measured, and the patients were divided into three diagnostic categories according to their serum TSH concentrations. 1) Hypothyroidism 2) Hyperthyroidism 3) Normal thyroid Results: A total of 127 individuals were part of the sample for the final analysis. The majority of study participants (77%) were females. A large number of the participants (92%) did not have a family history of thyroid dysfunction and the majority of the female participants, (85%) were not pregnant in the last two years. Furthermore, 98% of participants, were non-smokers. Conclusion: The findings of the current study showed a high prevalence of thyroid dysfunctions in individuals coming to FMIC for thyroid functions tests. The findings also indicated that aging and smoking are the factors associated with thyroid dysfunctions. Further studies are needed to find out the prevalence of and factors associated with thyroid dysfunctions. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Afghanistan" title="Afghanistan">Afghanistan</a>, <a href="https://publications.waset.org/abstracts/search?q=Kabul" title=" Kabul"> Kabul</a>, <a href="https://publications.waset.org/abstracts/search?q=hypothyroidism" title=" hypothyroidism"> hypothyroidism</a>, <a href="https://publications.waset.org/abstracts/search?q=hyperthyroidism" title=" hyperthyroidism"> hyperthyroidism</a>, <a href="https://publications.waset.org/abstracts/search?q=triiodothyronine" title=" triiodothyronine"> triiodothyronine</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroxine" title=" thyroxine"> thyroxine</a> </p> <a href="https://publications.waset.org/abstracts/140800/the-proportion-of-and-factors-associated-with-thyroid-dysfunction-among-individuals-referred-to-a-tertiary-care-facility-in-kabul-afghanistan" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/140800.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">175</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2195</span> Thyroid Cancer Treatment in Yemen Under Blockade Conditions and Absence of Radioactive Iodine</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Anis%20Al-Yakhiri">Anis Al-Yakhiri</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: The World Health Organization (WHO) classifies malignant epithelial thyroid tumors into four major groups (papillary, follicular, medullar and undifferentiated) . Papillary thyroid carcinoma (PTC) is the most common type, for about eight out of ten thyroid cancers belong to this histological type. Radioactive iodine (RAI) is considered effective for patients with total or nearly total thyroidectomy, but the beneficial effects of RAI are still controversial. War conditions forced us to study alternative methods of using radioactive iodine in the treatment of patients with PTC. Material and methods: Between January 2014 and June 2021, in Al-Yakhiri hospital, 57 Total Thyroidectomy with Radical BilateralNeckDissection (RBND) were performed, 50 for malignant disease,7 for false positive cytology.RBND involves surgical clearance of Levels II-VI. Mean age was 40.7 years old and 92% of the patients were female. 7(14%) patients had hypothyroidism which required preoperative thyroid hormone treatment. The Thyroid Stimulating Hormone- Suppression Therapy (TSH-ST) immediately started after RBND for mostpatients on the first day. It consisted in reducing the level of TSH< 0.1 mIU/L. Results: The Apron flap was used on most operations (40)80% and with lateral extensions had 10(20%). RBND involves surgical clearance of Levels II-VI performed in all operated patients, besides that, 4(8%) of them had resection of sternocleidomastoid muscle (SCM) and accessory nerve (XIn) and internal jugular vein (IJV) withclearance of Levels IB. The PTC was the most common 80.9% (38 patients from 47)by histopathological report. and 4(8%) patients of 50 had resection of sternocleidomastoid muscle (SCM) and accessory nerve (XIn) and internal jugular vein (IJV). The postoperative mortality rate not observed (0%). The postoperative morbidity rate was 22.8% (n =13).Seroma(8.7%),Hypocalcimia(7%), Wound infection(5.3%), Bleeding(1.8%). To suppress TSH and growth of any residual thyroid theTSH-ST (levothyroxine150 – 600mcg)was performed in all patients 57(100%) on the first day afterRBND. We tracked the results of treatment for two years in 30 patients with PTC, only 3 of them received radioactive iodine abroad. Biennial Recurrence rate for PTC appeared in one woman (2%), who had RAI postoperatively in the form of neck lymph nodes metastasis. Conclusion: For patients with PTC, thyroidectomy plus prophylacticRBND is a safe and efficient procedure and it results in lower recurrence rate. Postoperative treatment with exogenous thyroid hormone in doses sufficient to suppress TSH (not less than 150mcg), decreases incidence of recurrence. Total Thyroidectomy with RBND followed by TSH-ST, in our opinion, applicable optimal treatment scheme care for this patient population. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer" title="thyroid cancer">thyroid cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=Yemen%20war" title=" Yemen war"> Yemen war</a>, <a href="https://publications.waset.org/abstracts/search?q=absence%20of%20radioactive%20iodine" title=" absence of radioactive iodine"> absence of radioactive iodine</a>, <a href="https://publications.waset.org/abstracts/search?q=neck%20dissection" title=" neck dissection"> neck dissection</a>, <a href="https://publications.waset.org/abstracts/search?q=surgery%20results" title=" surgery results"> surgery results</a> </p> <a href="https://publications.waset.org/abstracts/167300/thyroid-cancer-treatment-in-yemen-under-blockade-conditions-and-absence-of-radioactive-iodine" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/167300.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">80</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2194</span> Follicular Thyroid Carcinoma in a Developing Country: A Retrospective Study of 10 Years</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Abdul%20Aziz">Abdul Aziz</a>, <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20Qamar%20Masood"> Muhammad Qamar Masood</a>, <a href="https://publications.waset.org/abstracts/search?q=Saadia%20Sattar"> Saadia Sattar</a>, <a href="https://publications.waset.org/abstracts/search?q=Saira%20Fatima"> Saira Fatima</a>, <a href="https://publications.waset.org/abstracts/search?q=Najmul%20Islam"> Najmul Islam</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: The most common endocrine tumor is thyroid cancer. Follicular Thyroid Carcinoma (FTC) accounts for 5%–10% of all thyroid cancers. Patients with FTC frequently present with more advanced stage diseases and a higher occurrence of distant metastases because of the propensity of vascular invasion. FTC is mainly treated with surgery, while radioactive iodine therapy is the main adjuvant therapy as per ATA guidelines. In many developing countries, surgical facilities and radioactive iodine are in short supply; therefore, understanding follicular thyroid cancer trends may help developing countries plan and use resources more effectively. Methodology: It was a retrospective observational study of FTC patients of age 18 years and above conducted at Aga Khan University Hospital, Karachi, from 1st January 2010 to 31st December 2019. Results: There were 404 patients with thyroid carcinoma, out of which forty (10.1%) were FTC. 50% of the patients were in the 41-60 years age group, and the female to male ratio was 1.5: 1. Twenty-four patients (60%) presented with complain of neck swelling followed by metastasis (20%) and compressive symptoms (20%). The most common site of metastasis was bone (87.5%), followed by lung (12.5%). The pre-operative thyroglobulin level was done in six out of eight metastatic patients (75%) in which it was elevated. This emphasizes the importance of checking thyroglobulin level in unusual presentation (bone pain, fractures) of a patient having neck swelling also to help in establishing the primary source of tumor. There was no complete documentation of ultrasound features of the thyroid gland in all the patients, which is an important investigation done in the initial evaluation of thyroid nodule. On FNAC, 50% (20 patients) had Bethesda category III-IV nodules, while 10% ( 4 patients ) had Bethesda category II. In sixteen patients, FNAC was not done as they presented with compressive symptoms or metastasis. Fifty percent had a total thyroidectomy and 50% had subtotal followed by completion thyroidectomy, plus ten patients had lymph node dissection, out of which seven had histopathological lymph node involvement. On histopathology, twenty-three patients (57.5%) had minimally invasive, while seventeen (42.5%) had widely invasive follicular thyroid carcinoma. The capsular invasion was present in thirty-three patients (82.5%); one patient had no capsular invasion, but there was a vascular invasion. Six patients' histopathology had no record of capsular invasion. In contrast, the lymphovascular invasion was present in twenty-six patients (65%). In this study, 65 % of the patients had clinical stage 1 disease, while 25% had stage 2 and 10% had clinical stage 4. Seventeen patients (42.5%) had received RAI 30-100 mCi, while ten patients (25%) received more than 100 mCi. Conclusion: FTC demographic and clinicopathological presentation are the same in Pakistan as compared to other countries. Surgery followed by RAI is the mainstay of treatment. Thus understanding the trend of FTC and proper planning and utilization of the resources will help the developing countries in effectively treating the FTC. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid%20carcinoma" title="thyroid carcinoma">thyroid carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=follicular%20thyroid%20carcinoma" title=" follicular thyroid carcinoma"> follicular thyroid carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=clinicopathological%20features" title=" clinicopathological features"> clinicopathological features</a>, <a href="https://publications.waset.org/abstracts/search?q=developing%20countries" title=" developing countries"> developing countries</a> </p> <a href="https://publications.waset.org/abstracts/135561/follicular-thyroid-carcinoma-in-a-developing-country-a-retrospective-study-of-10-years" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/135561.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">191</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2193</span> Enabling Non-invasive Diagnosis of Thyroid Nodules with High Specificity and Sensitivity</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sai%20Maniveer%20Adapa">Sai Maniveer Adapa</a>, <a href="https://publications.waset.org/abstracts/search?q=Sai%20Guptha%20Perla"> Sai Guptha Perla</a>, <a href="https://publications.waset.org/abstracts/search?q=Adithya%20Reddy%20P."> Adithya Reddy P.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Thyroid nodules can often be diagnosed with ultrasound imaging, although differentiating between benign and malignant nodules can be challenging for medical professionals. This work suggests a novel approach to increase the precision of thyroid nodule identification by combining machine learning and deep learning. The new approach first extracts information from the ultrasound pictures using a deep learning method known as a convolutional autoencoder. A support vector machine, a type of machine learning model, is then trained using these features. With an accuracy of 92.52%, the support vector machine can differentiate between benign and malignant nodules. This innovative technique may decrease the need for pointless biopsies and increase the accuracy of thyroid nodule detection. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid%20tumor%20diagnosis" title="thyroid tumor diagnosis">thyroid tumor diagnosis</a>, <a href="https://publications.waset.org/abstracts/search?q=ultrasound%20images" title=" ultrasound images"> ultrasound images</a>, <a href="https://publications.waset.org/abstracts/search?q=deep%20learning" title=" deep learning"> deep learning</a>, <a href="https://publications.waset.org/abstracts/search?q=machine%20learning" title=" machine learning"> machine learning</a>, <a href="https://publications.waset.org/abstracts/search?q=convolutional%20auto-encoder" title=" convolutional auto-encoder"> convolutional auto-encoder</a>, <a href="https://publications.waset.org/abstracts/search?q=support%20vector%20machine" title=" support vector machine"> support vector machine</a> </p> <a href="https://publications.waset.org/abstracts/182971/enabling-non-invasive-diagnosis-of-thyroid-nodules-with-high-specificity-and-sensitivity" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/182971.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">58</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2192</span> Early Hypothyroidism after Radiotherapy for Nasopharyngeal Carcinoma</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nejla%20Fourati">Nejla Fourati</a>, <a href="https://publications.waset.org/abstracts/search?q=Zied%20Fessi"> Zied Fessi</a>, <a href="https://publications.waset.org/abstracts/search?q=Fatma%20Dhouib"> Fatma Dhouib</a>, <a href="https://publications.waset.org/abstracts/search?q=Wicem%20Siala"> Wicem Siala</a>, <a href="https://publications.waset.org/abstracts/search?q=Leila%20Farhat"> Leila Farhat</a>, <a href="https://publications.waset.org/abstracts/search?q=Afef%20Khanfir"> Afef Khanfir</a>, <a href="https://publications.waset.org/abstracts/search?q=Wafa%20Mnejja"> Wafa Mnejja</a>, <a href="https://publications.waset.org/abstracts/search?q=Jamel%20Daoud"> Jamel Daoud</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: Radiation induced hypothyroidism in nasopharyngeal cancer (NPC) ranged from 15% to 55%. In reported data, it is considered as a common late complication of definitive radiation and is mainly observed 2 years after the end of treatment. The aim of this study was to evaluate the incidence of early hypothyroidism within 6 months after radiotherapy. Patients and methods: From June 2017 to February 2020, 35 patients treated with concurrent chemo-radiotherapy (CCR) for NPC were included in this prospective study. Median age was 49 years [23-68] with a sex ratio of 2.88. All patients received intensity modulated radiotherapy (IMRT) at a dose of 69.96 Gy in 33 daily fractions with weekly cisplatin (40mg/m²) chemotherapy. Thyroid stimulating hormone (TSH) and Free Thyroxine 4 (FT4) dosage was performed before the start of radiotherapy and 6 months after. Different dosimetric parameters for the thyroid gland were reported: the volume (cc); the mean dose (Dmean) and the %age of volume receiving more than 45 Gy (V45Gy). Wilcoxon Test was used to compare these different parameters between patients with or without hypothyroidism. Results: At baseline, 5 patients (14.3%) had hypothyroidism and were excluded from the analysis. For the remaining 30 patients, 9 patients (30%) developed a hypothyroidism 6 months after the end of radiotherapy. The median thyroid volume was 10.3 cc [4.6-23]. The median Dmean and V45Gy were 48.3 Gy [43.15-55.4] and 74.8 [38.2-97.9] respectively. No significant difference was noted for all studied parameters. Conclusion: Early hypothyroidism occurring within 6 months after CCR for NPC seems to be a common complication (30%) that should be screened. Good patient monitoring with regular dosage of TSH and FT4 makes it possible to treat hypothyroidism in asymptomatic phase. This would be correlated with an improvement in the quality of life of these patients. The results of our study do not show a correlation between the thyroid doses and the occurrence of hypothyroidism. This is probably related to the high doses received by the thyroid in our series. These findings encourage more optimization to limit thyroid doses and then the risk of radiation-induced hypothyroidism <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=nasopharyngeal%20carcinoma" title="nasopharyngeal carcinoma">nasopharyngeal carcinoma</a>, <a href="https://publications.waset.org/abstracts/search?q=hypothyroidism" title=" hypothyroidism"> hypothyroidism</a>, <a href="https://publications.waset.org/abstracts/search?q=early%20complication" title=" early complication"> early complication</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20dose" title=" thyroid dose "> thyroid dose </a> </p> <a href="https://publications.waset.org/abstracts/134506/early-hypothyroidism-after-radiotherapy-for-nasopharyngeal-carcinoma" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/134506.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">131</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2191</span> Stability Analysis for an Extended Model of the Hypothalamus-Pituitary-Thyroid Axis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Beata%20Jackowska-Zduniak">Beata Jackowska-Zduniak</a> </p> <p class="card-text"><strong>Abstract:</strong></p> We formulate and analyze a mathematical model describing dynamics of the hypothalamus-pituitary-thyroid homoeostatic mechanism in endocrine system. We introduce to this system two types of couplings and delay. In our model, feedback controls the secretion of thyroid hormones and delay reflects time lags required for transportation of the hormones. The influence of delayed feedback on the stability behaviour of the system is discussed. Analytical results are illustrated by numerical examples of the model dynamics. This system of equations describes normal activity of the thyroid and also a couple of types of malfunctions (e.g. hyperthyroidism). <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=mathematical%20modeling" title="mathematical modeling">mathematical modeling</a>, <a href="https://publications.waset.org/abstracts/search?q=ordinary%20differential%20equations" title=" ordinary differential equations"> ordinary differential equations</a>, <a href="https://publications.waset.org/abstracts/search?q=endocrine%20system" title=" endocrine system"> endocrine system</a>, <a href="https://publications.waset.org/abstracts/search?q=delay%20differential%20equation" title=" delay differential equation"> delay differential equation</a> </p> <a href="https://publications.waset.org/abstracts/52938/stability-analysis-for-an-extended-model-of-the-hypothalamus-pituitary-thyroid-axis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/52938.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">336</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2190</span> Clinical Implication of Hyper-Intense Signal Thyroid Incidentaloma on Time of Flight Magnetic Resonance Angiography</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Inseon%20Ryoo">Inseon Ryoo</a>, <a href="https://publications.waset.org/abstracts/search?q=Soo%20Chin%20Kim"> Soo Chin Kim</a>, <a href="https://publications.waset.org/abstracts/search?q=Hyena%20Jung"> Hyena Jung</a>, <a href="https://publications.waset.org/abstracts/search?q=Sangil%20Suh"> Sangil Suh</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objectives: The purpose of this study is to evaluate the clinical significance of hyper-intense signal thyroid incidentalomas on the time of flight magnetic resonance angiography (TOF-MRA) using correlation study with ultrasound (US). Methods: We retrospectively reviewed 3,505 non-contrast TOF-MRA performed at an institution between September 2014 and May 2017. Two radiologists correlated the thyroid incidentalomas detected on TOF-MRA with US features which was obtained within three months interval between MRA and US examinations in consensus method. Results: The prevalence of hyper-intense signal thyroid nodules incidentally detected on TOF-MRA was 1.2% (43/3505). Among them, 35 people (81.4%) underwent US examinations, and total 45 hyper-intense signal thyroid nodules were detected on US exams. Of these 45 nodules, 35 nodules (72.9%) were categorized as benign (K-TIRADS category 2) on US exams. Fine needle aspiration was performed on 9 nodules according to the indications recommended by Korean Society of Thyroid Radiology. All except one high-suspicious thyroid nodule were confirmed as benign (Bethesda 2) on cytologic exams. One high-suspicious nodule on US showed a non-diagnostic result (Bethesda 1) on cytologic exam. However, this nodule collapsed after aspiration of thick colloid material. Conclusions: Our study showed that the most hyper-intense signal thyroid nodules detected on TOF-MRA were benign. Therefore, if a hyper-intense signal incidentaloma is found on TOF-MRA, further evaluation, especially invasive biopsy of the nodules could be suspended unless the patient had other symptoms or clinical factors suggesting the need for further evaluation. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=incidentaloma" title="incidentaloma">incidentaloma</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20nodule" title=" thyroid nodule"> thyroid nodule</a>, <a href="https://publications.waset.org/abstracts/search?q=TOF%20MR%20angiography" title=" TOF MR angiography"> TOF MR angiography</a>, <a href="https://publications.waset.org/abstracts/search?q=ultrasound" title=" ultrasound"> ultrasound</a> </p> <a href="https://publications.waset.org/abstracts/93144/clinical-implication-of-hyper-intense-signal-thyroid-incidentaloma-on-time-of-flight-magnetic-resonance-angiography" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/93144.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">167</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2189</span> Frequency and Factors Associated with Thyroid Dysfunction: A Descriptive Cross-Sectional Study from a Tertiary Care Center in Kabul, Afghanistan</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Naeem%20Lakanwall">Mohammad Naeem Lakanwall</a>, <a href="https://publications.waset.org/abstracts/search?q=Jamshid%20Abdul-Ghafar"> Jamshid Abdul-Ghafar</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Endocrinopathies are a commonly occurring entity, particularly those of the thyroid gland; however, there is a lack of scientific literature from Afghanistan, a country with very limited health care facilities and resources. To our best knowledge, this is the first study aimed to describe the frequency of occurrence and factors associated with thyroid dysfunction in the Afghan population. The aim of this study is to estimate the frequency and to identify factors associated with thyroid dysfunction among individuals coming to a tertiary care facility in Kabul, Afghanistan. Methods: A cross-sectional study was conducted from July to Sep 2018 at the Department of Clinical Pathology, French Medical Institute for Mothers and Children (FMIC), Kabul, Afghanistan. Blood samples were obtained, serum TSH levels were analyzed, and the patients were divided into three diagnostic categories according to their serum TSH concentrations: 1) hypothyroidism, 2) hyperthyroidism, 3) normal. Results: A total of 127 individuals were included in the final analysis. The majority of study participants (77%) were females. A large number of the participants (92%) did not have a family history of thyroid dysfunction. 74% of the participants in the study had normal TSH levels classified as normal thyroid function, (14%) had lower TSH levels, and (12%) higher TSH levels, classified as hyper and hypothyroid, respectively. Conclusions: The findings of the current study showed a high frequency of thyroid dysfunctions from a single center. Further large-scale studies are needed to find out the prevalence and document this entity for better health outcomes in the country. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Afghanistan" title="Afghanistan">Afghanistan</a>, <a href="https://publications.waset.org/abstracts/search?q=factors" title=" factors"> factors</a>, <a href="https://publications.waset.org/abstracts/search?q=frequency" title=" frequency"> frequency</a>, <a href="https://publications.waset.org/abstracts/search?q=hypothyroid" title=" hypothyroid"> hypothyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=hyperthyroid" title=" hyperthyroid"> hyperthyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid" title=" thyroid"> thyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20stimulating%20hormone" title=" thyroid stimulating hormone"> thyroid stimulating hormone</a> </p> <a href="https://publications.waset.org/abstracts/135297/frequency-and-factors-associated-with-thyroid-dysfunction-a-descriptive-cross-sectional-study-from-a-tertiary-care-center-in-kabul-afghanistan" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/135297.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">171</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2188</span> Prevalence of Thyroid Disorders in Pregnancy in Northern Algeria</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Samira%20Akdader-Oudahmane">Samira Akdader-Oudahmane</a>, <a href="https://publications.waset.org/abstracts/search?q=Assia%20Kamel"> Assia Kamel</a>, <a href="https://publications.waset.org/abstracts/search?q=Lynda%20Lakabi"> Lynda Lakabi</a>, <a href="https://publications.waset.org/abstracts/search?q=Michael%20Bruce%20Zimmermann"> Michael Bruce Zimmermann</a>, <a href="https://publications.waset.org/abstracts/search?q=Zohra%20Hamouli-Said"> Zohra Hamouli-Said</a>, <a href="https://publications.waset.org/abstracts/search?q=Djamila%20Meskine"> Djamila Meskine</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Iodine is a trace element whose adequate intakes are essential during pregnancy to promote the correct growth and development of the fetus. Iodine deficiency is the cause of several disorders in foetal development, and thyroid disorders during pregnancy are associated with an increased risk of miscarriage or premature birth. The aim of this study was to assess the iodine status and thyroid function of pregnant women (PW) in northern Algeria. Methods: Healthy PW were recruited from an urban area (Algiers). Spot urine and venous blood samples were collected to assess iodine status (urinary iodine concentration, UIC) and serum thyroid hormones (TSH, FT4), and anti-thyroid peroxidase antibodies (TPO-Ab) concentrations. Results: The median UIC for the PW (n=172) in Algiers was 246,74µg/L, 244,68 µg/L, and 220,63µg/L, respectively, during the first, second, and third trimesters of pregnancy. Mean TSH and FT4 concentrations were within reference ranges in all groups of women. Among PW, 72.7%, 75.4%, and 75.5% in the first, second and third trimester were TPO-Ab+. Among PW, 14%, 10%, and 10% in the first, second and third trimester, respectively, with TPO -Ab+ had subclinical hypothyroidism. An analysis of the variations in the levels of the serum parameters (FT4, TSH and anti-TPO antibodies) was analyzed according to the UIC intervals admitted and show that these marker are predictive of thyroid function. Conclusion: In northern Algeria, median UICs indicate iodine sufficiency in PW. About 75% of PW are TPO-Ab+ and the prevalence of subclinical hypothyroidism is high. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid" title="thyroid">thyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=pregnant%20woman" title=" pregnant woman"> pregnant woman</a>, <a href="https://publications.waset.org/abstracts/search?q=urinary%20iodine" title=" urinary iodine"> urinary iodine</a>, <a href="https://publications.waset.org/abstracts/search?q=subclinical%20hypothyroidism" title=" subclinical hypothyroidism"> subclinical hypothyroidism</a> </p> <a href="https://publications.waset.org/abstracts/166232/prevalence-of-thyroid-disorders-in-pregnancy-in-northern-algeria" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/166232.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">78</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2187</span> Functional Analysis of Thyroid Peroxidase (TPO) Gene Mutations Detected in Patients with Thyroid Dyshormonogenesis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Biswabandhu%20Bankura">Biswabandhu Bankura</a>, <a href="https://publications.waset.org/abstracts/search?q=Srikanta%20Guria"> Srikanta Guria</a>, <a href="https://publications.waset.org/abstracts/search?q=Madhusudan%20Das"> Madhusudan Das</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: Thyroid peroxidase (TPO) is the key enzyme in the biosynthesis of thyroid hormones. We aimed to identify the spectrum of mutations in the TPO gene leading to hypothyroidism in the population of West Bengal to establish the genetic etiology of the disease. Methods: 200 hypothyroid patients (case) and their corresponding sex and age matched 200 normal individuals (control) were screened depending on their clinical manifestations. Genomic DNA was isolated from peripheral blood samples and TPO gene (Exon 7 to Exon 14) was amplified by PCR. The PCR products were subjected to sequencing to identify mutations. Results: Single nucleotide changes such as Glu 641 Lys, Asp 668 Asn, Thr 725 Pro, Asp 620 Asn, Ser 398 Thr, and Ala 373 Ser were found. Changes in the TPO were assayed in vitro to compare mutant and wild-type activities. Five mutants were enzymatically inactive in the guaiacol and iodide assays. This is a strong indication that the mutations are present at crucial positions of the TPO gene, resulting in inactivated TPO. Key Findings: The results of this study may help to develop a genetic screening protocol for goiter and hypothyroidism in the population of West Bengal. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid%20peroxidase" title="thyroid peroxidase">thyroid peroxidase</a>, <a href="https://publications.waset.org/abstracts/search?q=hypothyroidism" title=" hypothyroidism"> hypothyroidism</a>, <a href="https://publications.waset.org/abstracts/search?q=mutation" title=" mutation"> mutation</a>, <a href="https://publications.waset.org/abstracts/search?q=in%20vitro%20assay" title=" in vitro assay"> in vitro assay</a>, <a href="https://publications.waset.org/abstracts/search?q=transfection" title=" transfection"> transfection</a> </p> <a href="https://publications.waset.org/abstracts/20470/functional-analysis-of-thyroid-peroxidase-tpo-gene-mutations-detected-in-patients-with-thyroid-dyshormonogenesis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/20470.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">345</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2186</span> Functional Analysis of Thyroid Peroxidase Gene Mutations Detected in Patients with Thyroid Dyshormonogenesis</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Biswabandhu%20Bankura">Biswabandhu Bankura</a>, <a href="https://publications.waset.org/abstracts/search?q=Srikanta%20Guria"> Srikanta Guria</a>, <a href="https://publications.waset.org/abstracts/search?q=Madhusudan%20Das"> Madhusudan Das</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Purpose: Thyroid peroxidase (TPO) is the key enzyme in the biosynthesis of thyroid hormones. We aimed to identify the spectrum of mutations in the TPO gene leading to hypothyroidism in the population of West Bengal to establish the genetic etiology of the disease. Methods: 200 hypothyroid patients (case) and their corresponding sex and age matched 200 normal individuals (control) were screened depending on their clinical manifestations. Genomic DNA was isolated from peripheral blood samples and TPO gene (Exon 7 to Exon 14) was amplified by PCR. The PCR products were subjected to sequencing to identify mutations. Results: Single nucleotide changes such as Glu 641 Lys, Asp 668 Asn, Thr 725 Pro, Asp 620 Asn, Ser 398 Thr, and Ala 373 Ser were found. Changes in the TPO were assayed in vitro to compare mutant and wild-type activities. Five mutants were enzymatically inactive in the guaiacol and iodide assays. This is a strong indication that the mutations are present at crucial positions of the TPO gene, resulting in inactivated TPO. Key Findings: The results of this study may help to develop a genetic screening protocol for goiter and hypothyroidism in the population of West Bengal. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=thyroid%20peroxidase" title="thyroid peroxidase">thyroid peroxidase</a>, <a href="https://publications.waset.org/abstracts/search?q=hypothyroidism" title=" hypothyroidism"> hypothyroidism</a>, <a href="https://publications.waset.org/abstracts/search?q=mutation" title=" mutation"> mutation</a>, <a href="https://publications.waset.org/abstracts/search?q=in%20vitro%20assay" title=" in vitro assay"> in vitro assay</a>, <a href="https://publications.waset.org/abstracts/search?q=transfection" title=" transfection"> transfection</a> </p> <a href="https://publications.waset.org/abstracts/19059/functional-analysis-of-thyroid-peroxidase-gene-mutations-detected-in-patients-with-thyroid-dyshormonogenesis" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/19059.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">334</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2185</span> Papillary Thyroid Carcinoma Presenting as a Vascular Left Carotid Sheath Mass: A Case Report</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Karthikeyan%20M.">Karthikeyan M.</a>, <a href="https://publications.waset.org/abstracts/search?q=Paul%20M.%20J."> Paul M. J.</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This case report discusses a 54-year-old woman from Salem, Tamilnadu, who presented with a rare case of papillary thyroid carcinoma (PTC), manifesting as a hypervascular mass in the left carotid sheath. The patient had a two-and-a-half-month history of non-progressive neck swelling, with symptoms including dysphagia and a choking sensation. Clinical examination and investigations such as FNAC and CECT revealed a large vascular mass in the left neck region, initially perplexing the diagnosis. The patient underwent total thyroidectomy and excision of the left carotid sheath mass. Histopathology confirmed PTC. Postoperatively, the patient received Iodine-131 ablation and showed good recovery with no recurrence. This case highlights the diagnostic challenge and atypical presentation of PTC as a vascular neck mass, emphasizing the importance of a comprehensive approach in evaluating thyroid and neck lesions. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=lateral%20neck%20vascular%20mass" title="lateral neck vascular mass">lateral neck vascular mass</a>, <a href="https://publications.waset.org/abstracts/search?q=lateral%20aberrant%20thyroid" title=" lateral aberrant thyroid"> lateral aberrant thyroid</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20vascular%20swelling" title=" thyroid vascular swelling"> thyroid vascular swelling</a>, <a href="https://publications.waset.org/abstracts/search?q=smooth%20post%20op%20recovery" title=" smooth post op recovery"> smooth post op recovery</a> </p> <a href="https://publications.waset.org/abstracts/179226/papillary-thyroid-carcinoma-presenting-as-a-vascular-left-carotid-sheath-mass-a-case-report" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/179226.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">53</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2184</span> Experimental and Analytical Dose Assessment of Patient's Family Members Treated with I-131</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Marzieh%20Ebrahimi">Marzieh Ebrahimi</a>, <a href="https://publications.waset.org/abstracts/search?q=Vahid%20Changizi"> Vahid Changizi</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20Reza%20Kardan"> Mohammad Reza Kardan</a>, <a href="https://publications.waset.org/abstracts/search?q=Seyed%20Mahdi%20Hosseini%20Pooya"> Seyed Mahdi Hosseini Pooya</a>, <a href="https://publications.waset.org/abstracts/search?q=Parham%20Geramifar"> Parham Geramifar</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Radiation exposure to the patient's family members is one of the major concerns during thyroid cancer radionuclide therapy. The aim of this study was to measure the total effective dose of the family members by means of thermoluminescence personal dosimeter, and compare with those calculated by analytical methods. Eighty-five adult family members of fifty-one patients volunteered to participate in this research study. Considering the minimum and maximum range of dose rate from 15 µsv/h to 120 µsv/h at patients' release time, the calculated mean and median dose values of family members were 0.45 mSv and 0.28 mSv, respectively. Moreover, almost all family members’ doses were measured to be less than the dose constraint of 5 mSv recommended by Basic Safety Standards. Considering the influence parameters such as patient dose rate and administrated activity, the total effective doses of family members were calculated by TEDE and NRC formulas and compared with those of experimental results. The results indicated that, it is fruitful to use the quantitative calculations for releasing patients treated with I-131 and correct estimation of patients' family doses. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=effective%20dose" title="effective dose">effective dose</a>, <a href="https://publications.waset.org/abstracts/search?q=thermoluminescence" title=" thermoluminescence"> thermoluminescence</a>, <a href="https://publications.waset.org/abstracts/search?q=I-131" title=" I-131"> I-131</a>, <a href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer" title=" thyroid cancer"> thyroid cancer</a> </p> <a href="https://publications.waset.org/abstracts/50786/experimental-and-analytical-dose-assessment-of-patients-family-members-treated-with-i-131" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/50786.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">399</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">2183</span> Development of a Core Set of Clinical Indicators to Measure Quality of Care for Thyroid Cancer: A Modified-Delphi Approach</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Liane%20J.%20Ioannou">Liane J. Ioannou</a>, <a href="https://publications.waset.org/abstracts/search?q=Jonathan%20Serpell"> Jonathan Serpell</a>, <a href="https://publications.waset.org/abstracts/search?q=Cino%20Bendinelli"> Cino Bendinelli</a>, <a href="https://publications.waset.org/abstracts/search?q=David%20Walters"> David Walters</a>, <a href="https://publications.waset.org/abstracts/search?q=Jenny%20Gough"> Jenny Gough</a>, <a href="https://publications.waset.org/abstracts/search?q=Dean%20Lisewski"> Dean Lisewski</a>, <a href="https://publications.waset.org/abstracts/search?q=Win%20Meyer-Rochow"> Win Meyer-Rochow</a>, <a href="https://publications.waset.org/abstracts/search?q=Julie%20Miller"> Julie Miller</a>, <a href="https://publications.waset.org/abstracts/search?q=Duncan%20Topliss"> Duncan Topliss</a>, <a href="https://publications.waset.org/abstracts/search?q=Bill%20Fleming"> Bill Fleming</a>, <a href="https://publications.waset.org/abstracts/search?q=Stephen%20Farrell"> Stephen Farrell</a>, <a href="https://publications.waset.org/abstracts/search?q=Andrew%20Kiu"> Andrew Kiu</a>, <a href="https://publications.waset.org/abstracts/search?q=James%20Kollias"> James Kollias</a>, <a href="https://publications.waset.org/abstracts/search?q=Mark%20Sywak"> Mark Sywak</a>, <a href="https://publications.waset.org/abstracts/search?q=Adam%20Aniss"> Adam Aniss</a>, <a href="https://publications.waset.org/abstracts/search?q=Linda%20Fenton"> Linda Fenton</a>, <a href="https://publications.waset.org/abstracts/search?q=Danielle%20Ghusn"> Danielle Ghusn</a>, <a href="https://publications.waset.org/abstracts/search?q=Simon%20Harper"> Simon Harper</a>, <a href="https://publications.waset.org/abstracts/search?q=Aleksandra%20Popadich"> Aleksandra Popadich</a>, <a href="https://publications.waset.org/abstracts/search?q=Kate%20Stringer"> Kate Stringer</a>, <a href="https://publications.waset.org/abstracts/search?q=David%20Watters"> David Watters</a>, <a href="https://publications.waset.org/abstracts/search?q=Susannah%20Ahern"> Susannah Ahern</a> </p> <p class="card-text"><strong>Abstract:</strong></p> BACKGROUND: There are significant variations in the management, treatment and outcomes of thyroid cancer, particularly in the role of: diagnostic investigation and pre-treatment scanning; optimal extent of surgery (total or hemi-thyroidectomy); use of active surveillance for small low-risk cancers; central lymph node dissections (therapeutic or prophylactic); outcomes following surgery (e.g. recurrent laryngeal nerve palsy, hypocalcaemia, hypoparathyroidism); post-surgical hormone, calcium and vitamin D therapy; and provision and dosage of radioactive iodine treatment. A proven strategy to reduce variations in the outcome and to improve survival is to measure and compare it using high-quality clinical registry data. Clinical registries provide the most effective means of collecting high-quality data and are a tool for quality improvement. Where they have been introduced at a state or national level, registries have become one of the most clinically valued tools for quality improvement. To benchmark clinical care, clinical quality registries require systematic measurement at predefined intervals and the capacity to report back information to participating clinical units. OBJECTIVE: The aim of this study was to develop a core set clinical indicators that enable measurement and reporting of quality of care for patients with thyroid cancer. We hypothesise that measuring clinical quality indicators, developed to identify differences in quality of care across sites, will reduce variation and improve patient outcomes and survival, thereby lessening costs and healthcare burden to the Australian community. METHOD: Preparatory work and scoping was conducted to identify existing high quality, clinical guidelines and best practice for thyroid cancer both nationally and internationally, as well as relevant literature. A bi-national panel was invited to participate in a modified Delphi process. Panelists were asked to rate each proposed indicator on a Likert scale of 1–9 in a three-round iterative process. RESULTS: A total of 236 potential quality indicators were identified. One hundred and ninety-two indicators were removed to reflect the data capture by the Australian and New Zealand Thyroid Cancer Registry (ANZTCR) (from diagnosis to 90-days post-surgery). The remaining 44 indicators were presented to the panelists for voting. A further 21 indicators were later added by the panelists bringing the total potential quality indicators to 65. Of these, 21 were considered the most important and feasible indicators to measure quality of care in thyroid cancer, of which 12 were recommended for inclusion in the final set. The consensus indicator set spans the spectrum of care, including: preoperative; surgery; surgical complications; staging and post-surgical treatment planning; and post-surgical treatment. CONCLUSIONS: This study provides a core set of quality indicators to measure quality of care in thyroid cancer. This indicator set can be applied as a tool for internal quality improvement, comparative quality reporting, public reporting and research. Inclusion of these quality indicators into monitoring databases such as clinical quality registries will enable opportunities for benchmarking and feedback on best practice care to clinicians involved in the management of thyroid cancer. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=clinical%20registry" title="clinical registry">clinical registry</a>, <a href="https://publications.waset.org/abstracts/search?q=Delphi%20survey" title=" Delphi survey"> Delphi survey</a>, <a href="https://publications.waset.org/abstracts/search?q=quality%20indicators" title=" quality indicators"> quality indicators</a>, <a href="https://publications.waset.org/abstracts/search?q=quality%20of%20care" title=" quality of care"> quality of care</a> </p> <a href="https://publications.waset.org/abstracts/95328/development-of-a-core-set-of-clinical-indicators-to-measure-quality-of-care-for-thyroid-cancer-a-modified-delphi-approach" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/95328.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">180</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=4">4</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=5">5</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=6">6</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=7">7</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=8">8</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=9">9</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=10">10</a></li> <li class="page-item disabled"><span class="page-link">...</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=73">73</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=74">74</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=thyroid%20cancer&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>